Global reach Italfarmaco operates in multiple European countries plus the Americas (USA, Brazil) through controlled and affiliated entities, presenting multiple regional sales opportunities for ethical pharmaceutical products and potential partnerships.

Therapeutic focus Strong R&D emphasis on cardiovascular, immunology, and oncology areas, with recent clinical activity in Duchenne muscular dystrophy (DMD) using givinostat, suggesting opportunities for cardiovascular and rare disease collaborations, clinical partnerships, and companion diagnostics.

Manufacturing capacity Own modern, sophisticated facilities producing pre-filled syringes, sterile injections, and oral formulations, which supports contract manufacturing, toll manufacturing, and potential supply chain partnerships.

Leadership transition New CEO appointed effective January 2026, signaling potential strategic shifts, partnerships, or M&A activity; sales teams can engage to align with upcoming strategic initiatives and product launches.

Recent partnerships Strategic collaborations and licensing activity (e.g., Nerviano partnership; Multicare Pharma agreement) indicate openness to co-development, licensing, and regional commercialization deals that can be explored for portfolio expansion.